Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael R Ehrenstein

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
The Journal of Experimental Medicine|January 20, 2005
Impact of DNA ligase IV on nonhomologous end joining pathways during class switch recombination in human cellsQiang Pan-Hammarström, Anne-Marie Jones, Aleksi Lähdesmäki, et al.
BMJ Open|December 19, 2019
Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trialAlexis Jones, Patrick Muller, Caroline J Dore, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 22, 2007
Increased positive selection of B1 cells and reduced B cell tolerance to intracellular antigens in c1q-deficient miceHelen Ferry, Paul K Potter, Tanya L Crockford, et al.
Arthritis and Rheumatism|August 9, 2003
Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritisGeraldine Cambridge, Maria J Leandro, Jonathan C W Edwards, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 13, 2002
The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in miceJeremy S Brown, Tracy Hussell, Sarah M Gilliland, et al.
Frontiers in Immunology|August 22, 2017
Tumor Necrosis Factor (TNF) Bioactivity at the Site of an Acute Cell-Mediated Immune Response Is Preserved in Rheumatoid Arthritis Patients Responding to Anti-TNF TherapyRachel Byng-Maddick, Carolin T Turner, Gabriele Pollara, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 6, 2011
Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cellsNatalie A Carter, Rita Vasconcellos, Elizabeth C Rosser, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 4, 2009
Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritisGraham P Wright, Clare A Notley, Shao-An Xue, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2009
Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr micePaul A Blair, Karina A Chavez-Rueda, Jamie G Evans, et al.
Clinical Rheumatology|January 25, 2012
Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: addressing treatment outside the current NICE guidanceYee Chiu, Andrew J K Ostor, Anthony Hammond, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
The Journal of Experimental Medicine|January 20, 2005
Impact of DNA ligase IV on nonhomologous end joining pathways during class switch recombination in human cellsQiang Pan-Hammarström, Anne-Marie Jones, Aleksi Lähdesmäki, et al.
BMJ Open|December 19, 2019
Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trialAlexis Jones, Patrick Muller, Caroline J Dore, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 22, 2007
Increased positive selection of B1 cells and reduced B cell tolerance to intracellular antigens in c1q-deficient miceHelen Ferry, Paul K Potter, Tanya L Crockford, et al.
Arthritis and Rheumatism|August 9, 2003
Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritisGeraldine Cambridge, Maria J Leandro, Jonathan C W Edwards, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 13, 2002
The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in miceJeremy S Brown, Tracy Hussell, Sarah M Gilliland, et al.
Frontiers in Immunology|August 22, 2017
Tumor Necrosis Factor (TNF) Bioactivity at the Site of an Acute Cell-Mediated Immune Response Is Preserved in Rheumatoid Arthritis Patients Responding to Anti-TNF TherapyRachel Byng-Maddick, Carolin T Turner, Gabriele Pollara, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 6, 2011
Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cellsNatalie A Carter, Rita Vasconcellos, Elizabeth C Rosser, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 4, 2009
Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritisGraham P Wright, Clare A Notley, Shao-An Xue, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2009
Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr micePaul A Blair, Karina A Chavez-Rueda, Jamie G Evans, et al.
Clinical Rheumatology|January 25, 2012
Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: addressing treatment outside the current NICE guidanceYee Chiu, Andrew J K Ostor, Anthony Hammond, et al.
Pageof 7